ASD 141
Alternative Names: ASD-141Latest Information Update: 04 Mar 2024
At a glance
- Originator Ascendo Biotechnology
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants; TREML1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 07 Feb 2024 ASD 141 is available for licensing as of 07 Feb 2024. https://www.ascendobiotech.com/asd141/
- 07 Feb 2024 Preclinical trials in Solid tumours in Taiwan (Parenteral) before February 2024 (Ascendo Biotechnology pipeline, February 2024)
- 07 Feb 2024 FDA approves IND application for ASD 141 in Solid tumours before February 2024 (Ascendo Biotechnology pipeline, February 2024)